


Amendments to the Claims:

The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:


1. (Currently amended) A sterilized pharmaceutical preparation comprising at least one compound of the general formula (I)



wherein R is methyl, ethyl, isopropyl, butyl, 2-methyl-butyl, hexyl or cyclohexyl, ~~a straight chain or branched alkyl residue having 1—30 carbon atoms, a straight chain or branched alkenyl residue having 2—30 carbon atoms, a monocyclic or polycyclic alkyl residue having 3—30 carbon atoms, a monocyclic or polycyclic alkenyl residue having 4—30 carbon atoms, or a monocyclic or polycyclic aromatic residue having 6—30 carbon atoms, these residues being optionally substituted by one or several substituents and a pharmaceutically compatible inert carrier or diluent.~~

2. (Cancelled)

3. (Currently Amended) A pharmaceutical preparation comprising at least one compound to the general formula (I)



~~The pharmaceutical preparation according to claim 1, in the compound of formula (1) wherein R is isopropyl, butyl, 2-methyl-butyl, butyl hexyl, cyclohexyl~~ CH₂CH₂OH, CH₂CH₂CH₂OH, OR CH₂(CH₂)₂CH₂OH and a pharmaceutically compatible inert carrier or diluent.

4. (Previously presented) The pharmaceutical preparation according to claim 1, wherein the compound of formula (I), is Bis(O-cyclohexyl-dithiocarbonato)palladium(II), Bis(O-isopropyl-dithiocarbonato)palladium(II), Bis(O-ethyl-dithiocarbonato)palladium(II), Bis(O-(2-methyl)-butyl-dithiocarbonato)palladium(II), Bis(O-butyl-dithiocarbonato)palladium(II), Bis(O-hexyl-dithiocarbonato) palladium(II) or Bis(O-methyl)-dithiocarbonato palladium(II).

5. (Previously presented) The pharmaceutical preparation according to claim 1, comprising additionally an immunosuppressive compound selected from the group consisting of cyclosporine, rapamycin, 15-deocyspergualine, OKT3 and azathioprine.

6. (Previously presented) The pharmaceutical preparation according to claim 1, comprising additionally cytokines, interferon or other cytostatic agents.

7. (Previously presented) The pharmaceutical preparation according to claim 1, provided in a unit dosage form for administration to a mammal which requires treatment with an anticancer or anti-autoimmunic agent.

8. (Cancelled)

9. (Cancelled)

10. (Currently amended) ~~The method according to claim 9~~ A method for the treatment of a cancerous disease comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical preparation according to claim 1, wherein the cancerous disease is parvocellular bronchial carcinoma or colorectal carcinoma.

11. (Cancelled)

12. (Previously presented) A process for the production of a pharmaceutical preparation according to claim 1, comprising mixing the compound according to formula (I) with a pharmaceutically compatible carrier or diluent.

13. (Currently amended) ~~The method according to claim 9~~ A method for the treatment of a tumor comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical preparation according to claim 1, wherein the ~~solid~~ tumor is selected from the group consisting of glioma, a bladder tumor, a lung tumor, melanoma, a breast tumor and an ovarian tumor.

14. Cancelled.

15. (Currently amended) The method according to claim 13[[4]] wherein ~~tumors selected from the group consisting of glioma, bladder, lung, melanoma, breast and ovary are treated~~ the pharmaceutical preparation comprises a therapeutically effective amount of Bis(O-cyclohexyl-dithiocarbonato)palladium (II).

16. Cancelled

17. Cancelled